December 27, 2024

11 Medical Breakthroughs This Year

Explore medical breakthroughs from 2024, including advancements in Parkinson’s therapy, ulcerative colitis treatments, and gene therapy for hereditary deafness.

Conexiant

December 24, 2024

Merck to Halt Zinplava by January

Merck discontinuing Zinplava, an antibody drug designed to prevent the recurrence of a bacterial infection that can lead to fatal diarrhea, as disclosed on the FDA's website.

Reuters

December 23, 2024

FDA Green-Lights Second GLP-1 Generic Drug

The FDA has approved the first generic GLP-1 injection for type 2 diabetes management, maintaining the safety profile and emphasizing clinical monitoring requirements for adverse effects.

Conexiant

December 23, 2024

Trump Team Targets Immediate WHO Exit, Experts Say

"I have it on good authority that he plans to withdraw, probably on Day One or very early in his administration."

Reuters

December 19, 2024

FDA Resolves Lilly Drug Shortage Issue

The FDA has addressed the shortage of Eli Lilly's weight-loss drug and a lawsuit involving compounding pharmacies. Novo Nordisk's weight-loss drug remains in short supply.

Reuters

December 19, 2024

FDA Rejects New Bowel Disease Drug

The FDA declined to approve Zealand Pharma's bowel disease drug and sought an additional trial to confirm the drug's safety and efficacy, impacting thousands of adult patients in the United States.

Reuters

December 18, 2024

Does Anger at Health Care Drive Change?

In-depth exploration of public anger towards the American health care system throughout history, potential for change, and Hollywood's portrayal of health insurance-related events.

KFF Health News

December 17, 2024

Trump's Health Picks Clash on Vaccines, Policy

The selection of individuals for federal health agencies under President-elect Donald Trump presents conflicting views on matters such as abortion limits, vaccine safety, covid-19 responses, and the use of weight-loss medications.

KFF Health News

December 17, 2024

FDA Targets Unapproved GLP-1 Drug Sellers

The FDA has issued warning letters to companies for selling unapproved versions of popular diabetes and weight-loss drugs. The companies falsely labeled products for 'research use only' despite evidence showing they are intended for human use.

Reuters